To view this email as a web page, click here.
 
Highlights from MauiDerm 2017
 
Dermatology Times cover
View the full issue here.
IL-31 at center stage
A novel interleukin (IL) antagonist currently in phase 2 studies could advance the treatment of atopic dermatitis (AD), according to a dermatologist.
Learn more.
 
Biosimilar familiarity expands
Dermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.
Learn more.
 
Atopic dermatitis comorbidities
Emerging data suggest that atopic dermatitis is not just a skin disease. In terms of its impact on the whole patient and its potential for multi-organ involvement, it is a systemic disease, according to one dermatologist.
Learn more.
 
ADVERTISEMENT
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.